Skye Bioscience, Inc. (SKYE) stock
SKYENasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.09+0.01 (+0.93%)
Close on Nov 13, 2026Market cap $4.82MP/E –Yield –
Skye Bioscience r&d expenses
Research and development expenses are spending on new products and technology.
Skye Bioscience's R&D Expenses for the twelve months ending Sep 30, 2026 was $24.66M, down 36.2% year over year. For fiscal 2025 it was $42.36M, up 126.5% from the year before. Over ten years it grew 53.7% a year on average. The highest annual figure on record is $42.36M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.36M | +126.5% |
| FY2024 | Dec 31, 2024 | $18.70M | +221.4% |
| FY2023 | Dec 31, 2023 | $5.82M | -3.2% |
| FY2022 | Dec 31, 2022 | $6.01M | +105.1% |
| FY2021 | Dec 31, 2021 | $2.93M | +50.8% |
| FY2020 | Dec 31, 2020 | $1.94M | -13.1% |
| FY2019 | Dec 31, 2019 | $2.24M | +578.2% |
| FY2018 | Dec 31, 2018 | $329.97K | +6.0% |
| FY2017 | Dec 31, 2017 | $311.30K | -66.8% |
| FY2016 | Dec 31, 2016 | $939.04K | +63.0% |
| FY2015 | Dec 31, 2015 | $576.09K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.32M | -85.9% |
| Q2 FY2026 | Jun 30, 2026 | $3.94M | -72.5% |
| Q1 FY2026 | Mar 31, 2026 | $7.94M | +10.3% |
| Q4 FY2025 | Dec 31, 2025 | $11.47M | +47.2% |
| Q3 FY2025 | Sep 30, 2025 | $9.36M | +91.6% |
| Q2 FY2025 | Jun 30, 2025 | $14.34M | +251.5% |
| Q1 FY2025 | Mar 31, 2025 | $7.20M | +269.8% |
| Q4 FY2024 | Dec 31, 2024 | $7.79M | +389.7% |
| Q3 FY2024 | Sep 30, 2024 | $4.88M | +289.2% |
| Q2 FY2024 | Jun 30, 2024 | $4.08M | +128.1% |
| Q1 FY2024 | Mar 31, 2024 | $1.95M | +64.3% |
| Q4 FY2023 | Dec 31, 2023 | $1.59M | +3.5% |
| Q3 FY2023 | Sep 30, 2023 | $1.25M | -29.6% |
| Q2 FY2023 | Jun 30, 2023 | $1.79M | +25.3% |
| Q1 FY2023 | Mar 31, 2023 | $1.18M | -6.4% |
| Q4 FY2022 | Dec 31, 2022 | $1.54M | +38.1% |
| Q3 FY2022 | Sep 30, 2022 | $1.78M | +443.7% |
| Q2 FY2022 | Jun 30, 2022 | $1.43M | +62.1% |
| Q1 FY2022 | Mar 31, 2022 | $1.27M | +107.6% |
| Q4 FY2021 | Dec 31, 2021 | $1.11M | +200.9% |
| Q3 FY2021 | Sep 30, 2021 | $327.73K | -5.3% |
| Q2 FY2021 | Jun 30, 2021 | $880.67K | +105.5% |
| Q1 FY2021 | Mar 31, 2021 | $609.66K | -23.8% |
| Q4 FY2020 | Dec 31, 2020 | $370.05K | -48.3% |
| Q3 FY2020 | Sep 30, 2020 | $346.22K | -32.5% |
| Q2 FY2020 | Jun 30, 2020 | $428.53K | -37.7% |
| Q1 FY2020 | Mar 31, 2020 | $799.61K | +149.1% |
| Q4 FY2019 | Dec 31, 2019 | $715.93K | +201.2% |
| Q3 FY2019 | Sep 30, 2019 | $513.00K | +662.4% |
| Q2 FY2019 | Jun 30, 2019 | $688.04K | – |
| Q1 FY2019 | Mar 31, 2019 | $320.99K | +1183.9% |
| Q4 FY2018 | Dec 31, 2018 | $237.68K | +239.5% |
| Q3 FY2018 | Sep 30, 2018 | $67.29K | -24.0% |
| Q2 FY2018 | Jun 30, 2018 | $0 | -100.0% |
| Q1 FY2018 | Mar 31, 2018 | $25.00K | -72.9% |
| Q4 FY2017 | Dec 31, 2017 | $70.00K | -73.4% |
| Q3 FY2017 | Sep 30, 2017 | $88.55K | – |
| Q2 FY2017 | Jun 30, 2017 | $60.65K | – |
| Q1 FY2017 | Mar 31, 2017 | $92.10K | – |
| Q4 FY2016 | Dec 31, 2016 | $263.20K | – |
See a number that looks wrong?